Intercept Pharmaceuticals (NASDAQ:ICPT) reported Q4 2017 earnings this Morning, coming in at ($4.43) per share, missing Wall Street’s estimates of ($3.39) per Share. Revenue for the quarter came in at $37.69 million missing the streets estimates of $39.01 million Recent Insider Trading for Intercept Pharmaceuticals (NASDAQ:ICPT)
- On 10/2/2017 David Shapiro, CMO, sold 349 with an average share price of $58.90 per share and the total transaction amounting to $20,556.10.
- On 10/2/2017 Mark Pruzanski, CEO, sold 1,532 with an average share price of $58.87 per share and the total transaction amounting to $90,188.84.
- On 10/2/2017 Rachel Mcminn, Insider, sold 283 with an average share price of $58.89 per share and the total transaction amounting to $16,665.87.
- On 10/2/2017 Richard J Kim, SVP, sold 48 with an average share price of $58.10 per share and the total transaction amounting to $2,788.80.
- On 10/2/2017 Sandip Kapadia, CFO, sold 354 with an average share price of $58.83 per share and the total transaction amounting to $20,825.82.
- On 9/1/2017 David Shapiro, CMO, sold 1,250 with an average share price of $117.43 per share and the total transaction amounting to $146,787.50.
Recent Trading for Intercept Pharmaceuticals (NASDAQ:ICPT) Shares of Intercept Pharmaceuticals closed the previous trading session at 52.45 down -0.96 1.80% with shares trading hands.